Maze Therapeutics Inc. Common Stock (MAZE)
Stock · NASDAQ · Health Care
$27.53as of 10/16/2026
Price chart
Active signals
MAZE Signal Track Record
How signals performed across all stocks →What MAZE's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 6 | -3.5% | 50% | September 18, 2026 |
| Bollinger Band Breakout | 5 | +0.9% | 60% | August 18, 2026 |
| Bollinger Band Breakdown | 4 | +2.1% | 50% | September 9, 2026 |
| Any 20-session window (baseline) | +0.1% | 50% |
Computed by MarketWall from daily closing prices since November 14, 2025. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About MAZE
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibit…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 141
- Website
- www.mazetx.com/
Fundamentals
- 1-day range
- $25.97$27.09
- Market cap
- $1.58B
- P/E (trailing)
- —
- P/E (forward)
- -8.26
- EPS (trailing)
- $-2.51
- Dividend yield
- —
- Beta
- 1.01
- Avg. volume
- 581.1K
Forecasts
12 analyst ratings
Maze Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- MAZEMaze Therapeutics Inc. Common Stock$27.53▲ 0.18%Market cap $1.58BP/E —$21.95$53.65
- SLBTSL Science Holding Limited Ordinary Shares$1.53▼ 1.29%Market cap $1.53BP/E —$1.42$14.5
- IMCRImmunocore Holdings plc American Depositary Shares$29.4▼ 0.27%Market cap $1.66BP/E —$27.5$40.71
- VIRVir Biotechnology Inc. Common Stock$9.96▼ 4.87%Market cap $1.48BP/E —$4.82$12
- RXRXRecursion Pharmaceuticals Inc. Class A Common Stock$3.46▼ 16.71%Market cap $1.69BP/E —$2.77$7.18
- TSHATaysha Gene Therapies Inc. Common Stock$3.62▼ 2.95%Market cap $1.82BP/E —$3.46$7.3
- GLUEMonte Rosa Therapeutics Inc. Common Stock$9.74▼ 3.75%Market cap $1.33BP/E —$8.94$25.77
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MAZE Maze Therapeutics Inc. Common Stock | $1.58B | — | $27.53 | ▲ 0.18% | $21.95$53.65 |
| SLBT SL Science Holding Limited Ordinary Shares | $1.53B | — | $1.53 | ▼ 1.29% | $1.42$14.5 |
| IMCR Immunocore Holdings plc American Depositary Shares | $1.66B | — | $29.4 | ▼ 0.27% | $27.5$40.71 |
| VIR Vir Biotechnology Inc. Common Stock | $1.48B | — | $9.96 | ▼ 4.87% | $4.82$12 |
| RXRX Recursion Pharmaceuticals Inc. Class A Common Stock | $1.69B | — | $3.46 | ▼ 16.71% | $2.77$7.18 |
| TSHA Taysha Gene Therapies Inc. Common Stock | $1.82B | — | $3.62 | ▼ 2.95% | $3.46$7.3 |
| GLUE Monte Rosa Therapeutics Inc. Common Stock | $1.33B | — | $9.74 | ▼ 3.75% | $8.94$25.77 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026Yahoo · 10/6/2026
- 3 Small-Cap Stocks With Catalysts That Could Put Them in the SpotlightYahoo · 10/5/2026
- Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?Yahoo · 9/29/2026
- Maze Therapeutics (MAZE) Shares Moved, So What Is Driving Attention Now?Yahoo · 9/25/2026
- HC Wainwright & Co. Reiterates Buy on Maze Therapeutics, Maintains $110 Price TargetBenzinga · 9/24/2026
- Maze Therapeutics Shares Rise 2.9% After CIBC Initiates CoverageYahoo · 9/23/2026
- Citigroup Initiates Coverage On Maze Therapeutics with Buy Rating, Announces Price Target of $50Benzinga · 9/23/2026
- TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On WednesdayBenzinga · 9/23/2026
Insider Activity
Insider Actions →- Bernstein Harold · October 1, 2026 · Option Exercise16.1K @ $10.42
- Bernstein Harold · October 1, 2026 · Sale16.1K @ $26.93
- Coloma Jason V · October 1, 2026 · Sale31.9K @ $27.02
- Coloma Jason V · October 1, 2026 · Sale2.6K @ $27.02
- Dandekar Atul · September 29, 2026 · Option Exercise7.5K @ $10.42
- Dandekar Atul · September 29, 2026 · Sale7.5K @ $27.06
- Bernstein Harold · September 4, 2026 · Sale9.7K @ $26.22
- Dandekar Atul · September 3, 2026 · Sale3.2K @ $26.01
- Courtney Phillips · September 3, 2026 · Sale22 @ $25.78
- Courtney Phillips · September 3, 2026 · Sale2.0K @ $26.01
- Coloma Jason V · September 3, 2026 · Sale129 @ $25.77
- Coloma Jason V · September 3, 2026 · Sale11.3K @ $26.01
- Bernstein Harold · September 3, 2026 · Sale59 @ $25.78
- Bernstein Harold · September 3, 2026 · Sale5.1K @ $26.01
- Dandekar Atul · September 3, 2026 · Sale36 @ $25.81
Institutional Ownership
March 31, 2026
- Total shares held
- 51.71M
- Total value held
- $1.53B
- Institutional holders
- 165
- Unknown4.57M
- Unknown4.47M
- Unknown4.12M
- Unknown3.48M
- Unknown2.86M
- Unknown2.74M
- Unknown2.57M
- Unknown1.70M
- Unknown1.60M
- Unknown1.44M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Pompe Disease Market Expected to Grow Through 2036
A new market report projects expansion in the Pompe Disease sector from 2026 to 2036, driven by next-generation enzyme replacement therapies and pipeline innovation. This industry growth is relevant to Maze Therapeutics, which operates in this therapeutic area. The report highlights broader market trends rather than company-specific financial results.
Pompe Disease Market Expected to Grow Through 2036. A new market report projects expansion in the Pompe Disease sector from 2026 to 2036, driven by next-generation enzyme replacement therapies and pipeline innovation. This industry growth is relevant to Maze Therapeutics, which operates in this therapeutic area. The report highlights broader market trends rather than company-specific financial results.